[Clinical significance of 2-6 sialyl Le(a) antigen assay as a tumor marker]. 1990

R Kannagi, and S Itai, and R Harada
Department of Laboratory Medicine and Clinical Sciences, Faculty of Medicine, Kyoto University.

UI MeSH Term Description Entries
D007983 Lewis Blood Group Antigens Carbohydrate antigens structurally related to the ABH BLOOD-GROUP SYSTEM. They may occur as a modification of saccharide chains on glycolipids or glycoproteins on cell surfaces or in plasma, or as free oligosaccharides in secretions. Lewis antigens are not synthesized in blood cells. Instead Lewis glycolipids present in plasma are absorbed onto the surface of ERYTHROCYTES; LYMPHOCYTES; and PLATELETS. The phenotypes Le(a) and Le(b) are the result of the actions of two genes the Le gene (fucosyltransferase FUT3) and the Se gene (fucosyltransferase FUT2) on the precursor carbohydrate, glycolipid or glycoprotein. Other FUCOSYLTRANSFERASES can also synthesize the Lewis antigens. Blood Group Lewis Related Antigens,Lewis Antigen Related Tumor-Associated Antigens,Lewis Antigens,Lewis Blood Group Related Antigens,Lewis Blood Group Related Tumor-Associated Antigens,Lewis Blood-Group System,Lewis Related Antigens,Lewis System,Sialyl Lewis Antigens,Le Antigens,Le(a) Blood Group System,Antigens, Lewis,Antigens, Lewis Related,Antigens, Sialyl Lewis,Blood-Group System, Lewis,Lewis Antigen Related Tumor Associated Antigens,Lewis Blood Group Related Tumor Associated Antigens,Lewis Blood Group System
D009844 Oligosaccharides Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form. Oligosaccharide
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004067 Digestive System Neoplasms Tumors or cancer of the DIGESTIVE SYSTEM. Cancer of Digestive System,Digestive System Cancer,Cancer of the Digestive System,Neoplasms, Digestive System,Cancer, Digestive System,Cancers, Digestive System,Digestive System Cancers,Digestive System Neoplasm,Neoplasm, Digestive System
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

R Kannagi, and S Itai, and R Harada
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
R Kannagi, and S Itai, and R Harada
February 1990, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!